Related references
Note: Only part of the references are listed.A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System
Sung-Hoon Jung et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
James E. McDonald et al.
CLINICAL CANCER RESEARCH (2017)
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
Efstathios Kastritis et al.
HAEMATOLOGICA (2017)
Genomic complexity of multiple myeloma and its clinical implications
Salomon Manier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
Efstathios Kastritis et al.
HAEMATOLOGICA (2017)
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
Michele Cavo et al.
LANCET ONCOLOGY (2017)
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
N. Tandon et al.
BLOOD CANCER JOURNAL (2017)
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy
Hyungwoo Cho et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Evolutionary biology of high-risk multiple myeloma
Charlotte Pawlyn et al.
NATURE REVIEWS CANCER (2017)
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma
Leo Rasche et al.
BLOOD (2017)
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)
Cristina Nanni et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation
Francesca Patriarca et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders
Franco Dammacco et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2015)
State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings
Charles Mesguich et al.
EUROPEAN JOURNAL OF RADIOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
Constantin Lapa et al.
ONCOTARGET (2014)
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
Saad Z. Usmani et al.
BLOOD (2013)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma
Rosa Fonti et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
Elena Zamagni et al.
BLOOD (2011)
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Twyla B. Bartel et al.
BLOOD (2009)